Benefit-Risk Assessment for PD-1/PD-L1 Inhibitors in the Treatment of Non-Small Cell Lung Cancer
Li Zhuangqi, Yang Yue
Asian Journal of Social Pharmacy . 2022, (3): 253 -259 .